Leishmaniasis: Evidence-Based Clinical Guidance

Leishmaniasis is caused by Leishmania protozoa transmitted by sandfly bites, presenting in visceral, cutaneous, or mucocutaneous forms. Visceral leishmaniasis (kala-azar) causes fever, splenomegaly, and pancytopaenia. Amphotericin B and miltefosine are first-line treatments.

High-quality evidenceLast reviewed: 2026Guideline year: 2024Evidence: v1

Evidence Overview

Leishmaniasis is supported by high-quality clinical evidence. Current authority mapping includes 4 diagnostic tests and 2 treatment options, enabling structured evidence-based clinical guidance.

Guideline Summary

  • •Clinical guidance for Leishmaniasis emphasizes early severity assessment, comorbidity review, and risk-adjusted management decisions.
  • •Guideline workup uses targeted diagnostic confirmation, including rK39 Rapid Diagnostic Test, Bone Marrow Aspirate, Serology (ELISA) when clinically indicated.
  • •Therapy is escalated stepwise, starting with Amphotericin B and Miltefosine, then adapting to response and safety profile.

Diagnostic Evidence

  • •Diagnostic probability for Leishmaniasis is established by combining history, examination, and objective findings.
  • •Key confirmation tools include rK39 Rapid Diagnostic Test, Bone Marrow Aspirate, Serology (ELISA), Blood PCR.
  • •Guideline-based diagnosis favors staged testing: rule out urgent causes first, then refine etiology with condition-directed investigations.

Treatment Evidence

First-line Therapy

  • •First-line evidence-supported options include Amphotericin B and Miltefosine when clinically appropriate.
  • •Dose titration and treatment sequencing should follow guideline-defined efficacy and safety checkpoints.

Alternative Therapies

  • •Alternative strategies include switching therapeutic class, combination therapy, or referral pathways for non-response.
  • •Monitoring requirements should be individualized based on age, organ function, interactions, and treatment duration.

Evidence Limitations

  • •Evidence translation for Leishmaniasis depends on patient phenotype, disease stage, and comorbidity burden.
  • •Guideline recommendations can differ by region, available diagnostics, and drug access.

Clinical Importance

  • •Leishmaniasis carries meaningful clinical impact because delayed recognition can increase complications, care intensity, and recovery time.
  • •Infectious risk requires attention to transmission control, source management, and antimicrobial stewardship.

Primary Sources

Guideline Bodies

  • •WHO
  • •CDC
  • •IDSA

Primary Sources

  • •Major international clinical guideline statements
  • •Systematic reviews and meta-analyses in peer-reviewed journals
  • •Condition-specific consensus pathways and safety updates

Evidence Notes

  • •Antimicrobial guidance changes with resistance patterns and regional epidemiology.
  • •Selection drivers: infectious disease; >=2 tests and >=2 drugs in graph.
  • •This authority page summarizes evidence patterns and does not replace clinician judgment.

Internal Clinical Linking

Condition Core

Leishmaniasis overview

Condition Tests

rK39 Rapid Diagnostic TestBone Marrow AspirateSerology (ELISA)Blood PCR

Condition Drugs

Amphotericin BMiltefosine

Symptom Hubs

FeverWeight LossFatigue

Need structured triage for this condition profile?

Use AI Symptom Checker for differential orientation, urgency prioritization, and next-step guidance.

Start Free AI Analysis →

Medical References

Content on this page is informed by evidence-based clinical sources including: